EGF Antikörper (Middle Region)
-
- Target Alle EGF Antikörper anzeigen
- EGF (Epidermal Growth Factor (EGF))
-
Bindungsspezifität
- Middle Region
- Reaktivität
- Human, Maus, Ratte, Schwein, Hund, Kaninchen, Pferd
-
Wirt
- Kaninchen
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser EGF Antikörper ist unkonjugiert
-
Applikation
- Western Blotting (WB)
- Sequenz
- ITIDFLTDKL YWCDAKQSVI EMANLDGSKR RRLTQNDVGH PFAVAVFEDY
- Homologie
- Dog: 86%, Horse: 93%, Human: 100%, Mouse: 79%, Pig: 93%, Rabbit: 93%, Rat: 86%
- Produktmerkmale
- This is a rabbit polyclonal antibody against EGF. It was validated on Western Blot using a cell lysate as a positive control.
- Aufreinigung
- Affinity Purified
- Immunogen
- The immunogen is a synthetic peptide directed towards the middle region of human EGF
- Top Product
- Discover our top product EGF Primärantikörper
-
-
- Applikationshinweise
- Optimal working dilutions should be determined experimentally by the investigator.
- Kommentare
-
Antigen size: 1207 AA
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Konzentration
- Lot specific
- Buffer
- Liquid. Purified antibody supplied in 1x PBS buffer with 0.09 % (w/v) sodium azide and 2 % sucrose.
- Konservierungsmittel
- Sodium azide
- Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Handhabung
- Avoid repeated freeze-thaw cycles.
- Lagerung
- -20 °C
- Informationen zur Lagerung
- For short term use, store at 2-8°C up to 1 week. For long term storage, store at -20°C in small aliquots to prevent freeze-thaw cycles.
-
-
Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 14, Issue 11, pp. 3367-71, (2008) (PubMed).
: "
-
Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 14, Issue 11, pp. 3367-71, (2008) (PubMed).
-
- Target
- EGF (Epidermal Growth Factor (EGF))
- Andere Bezeichnung
- EGF (EGF Produkte)
- Synonyme
- HOMG4 antikoerper, URG antikoerper, AI790464 antikoerper, CEGF antikoerper, epidermal growth factor antikoerper, pro-epidermal growth factor antikoerper, EGF antikoerper, egf antikoerper, CpipJ_CPIJ020278 antikoerper, Egf antikoerper
- Hintergrund
-
Epidermal growth factor has a profound effect on the differentiation of specific cells in vivo and is a potent mitogenic factor for a variety of cultured cells of both ectodermal and mesodermal origin. The EGF precursor is believed to exist as a membrane-
Alias Symbols: URG, HOMG4
Protein Interaction Partner: EGFR, PCGF2, UBE2I, SREBF1, LMNB1, EMD, LMNA, ZFYVE28, PIK3R2, ADAM12, DUSP3, VTN, ERBB3, ERBB2, NRG1, EGF, CPM, ADRBK1, GRB2, MAPKAPK2, RPS6KA5, FNBP1,
Protein Size: 1207 - Molekulargewicht
- 6 kDa
- Gen-ID
- 1950
- NCBI Accession
- NM_001963, NP_001954
- UniProt
- P01133
- Pathways
- NF-kappaB Signalweg, RTK Signalweg, Fc-epsilon Rezeptor Signalübertragung, EGFR Signaling Pathway, Neurotrophin Signalübertragung, Regulation of Carbohydrate Metabolic Process, Hepatitis C, Protein targeting to Nucleus, Interaction of EGFR with phospholipase C-gamma, Thromboxane A2 Receptor Signaling, EGFR Downregulation
-